Financings for Feb. 18, 2020

Published

February 18, 2020

Financings for Feb. 18, 2020

Omass Therapeutics, of Oxford, U.K., which is harnessing mass spectrometry and other biophysical technologies to drive drug discovery, said it completed an extended series A financing of £27.5 million (US$35.757 million) from existing investors Syncona Ltd. and Oxford Sciences Innovation, bringing the total series A round to £41.5 million…

MORERelated News
Novel drug-discovery approach lands big backers
UK-based OMass Therapeutics is leaning on a proprietary form of native mass spectrometry to help develop small-molecule drugs for rare...
OMass Therapeutics: The 21st Century Vertex?
Originally spun out of Oxford University, biotech firm OMass Therapeutics today completed an impressive $100m series B round. CEO Ros...
No ‘easy targets’ for Omass, which adds $95M series B for small-molecule work
OMass Therapeutics Ltd. has raised £75.5 million (US$94.6 million) in a series B round, as it continues to advance five...